-
公开(公告)号:US11802132B2
公开(公告)日:2023-10-31
申请号:US16969772
申请日:2019-02-22
Applicant: DANA-FARBER CANCER INSTITUTE, INC.
Inventor: Jun Qi , Lei Wu , Kenneth C. Anderson , Yan Song , Paul Park , Dharminder Chauhan
IPC: C07D495/14 , C07D211/60 , A61P35/00
CPC classification number: C07D495/14 , A61P35/00 , C07D211/60
Abstract: Provided herein are bifunctional compounds that bind a target protein (e.g., a selected protein) and/or induce ubiquitination for degradation of the target protein. In particular, provided are compounds that bind a bromodomain or bromodomain-containing protein (e.g., BET proteins) or histone methyltransferases (HMTs, e.g., enhancer of zeste homolog 1 (EZH1), or FKBP12) and can promote its degradation by recruiting it to the ubiquitin receptor RPN13 (e.g., RA190), for proteasomal degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating and/or preventing diseases (e.g., proliferative diseases, cancers, benign neoplasms, pathological angiogenesis, inflammatory diseases, and autoimmune diseases) and musculoskeletal diseases, and methods of inducing the degradation of a target (e.g., a target protein) by recruiting it to the ubiquitin receptor RPN13 of the proteasome in a subject by administering a compound or composition described herein.
-
公开(公告)号:US20220227700A1
公开(公告)日:2022-07-21
申请号:US17596466
申请日:2020-06-12
Applicant: DANA-FARBER CANCER INSTITUTE, INC.
IPC: C07C233/81 , C07D495/04 , C07D213/40 , C07D215/38 , C07D209/86 , C07D277/82 , C07D217/02 , C07D333/66 , C07C317/32 , C07D211/58 , C07D233/61 , A61P35/00
Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC3 activity.
-
公开(公告)号:US20220241425A1
公开(公告)日:2022-08-04
申请号:US17617226
申请日:2020-06-17
Applicant: DANA-FARBER CANCER INSTITUTE, INC.
Inventor: Jun Qi , Deyao Li , Virangika K. Wimalasena , Paul Park
IPC: A61K47/54 , C07D471/04 , C07D413/14 , C07D401/14 , C07D417/14
Abstract: Disclosed are bispecific compounds (degraders) that target EP300/CBP for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.
-
-